Current Status of Dapagliflozin in Congestive Heart Failure

Area of Science:

• Cardiology
• Pharmacology
• Endocrinology

Background:

• Heart failure (HF) is a growing global health concern with significant morbidity, mortality, and economic impact.
• Current HF treatments are evolving with new pharmacological agents and devices.
• The sodium-glucose cotransporter 2 inhibitor (SGLT-2i) class has emerged as a novel therapeutic option.

Purpose of the Study:

• To review the efficacy and safety of dapagliflozin in symptomatic heart failure (HF) patients.
• To assess dapagliflozin's impact on cardiovascular mortality and HF hospitalizations.
• To evaluate dapagliflozin's role in patients with and without type 2 diabetes.

Main Methods:

• Review of clinical data and studies on dapagliflozin in HF management.
• Analysis of cardiovascular outcomes and safety profiles from relevant trials.
• Evaluation of dapagliflozin's effectiveness in diverse patient populations, including those with type 2 diabetes.

Main Results:

• Dapagliflozin (10 mg/day) significantly reduces cardiovascular mortality and hospitalization for HF.
• Benefits were observed in patients with and without type 2 diabetes, including those at risk for atherosclerotic disease.
• Dapagliflozin demonstrated a favorable safety profile, comparable to other indications and well-tolerated by patients.

Conclusions:

• Dapagliflozin is a well-tolerated and effective novel treatment for symptomatic heart failure (HF).
• It offers significant benefits in reducing mortality and hospitalizations, supporting its role in current HF therapy.
• Further research is warranted to optimize dapagliflozin's clinical application and expand its evidence base.